Department of Orthopaedic Surgery, Dartmouth-Hitchcock Medical Center, Lebanon, NH.
Department of Orthopaedic Surgery, Rush University Medical Center, Chicago, IL.
J Arthroplasty. 2020 Oct;35(10):2715-2729. doi: 10.1016/j.arth.2020.05.037. Epub 2020 May 28.
Oral and intravenous (IV) acetaminophen has become widely used perioperatively as part of a multi-modal pain management protocol for primary total joint arthroplasty (TJA). The purpose of our study is to evaluate the efficacy and safety of acetaminophen in support of the combined clinical practice guidelines of the American Association of Hip and Knee Surgeons, American Academy of Orthopaedic Surgeons, Hip Society, Knee Society, and American Society of Regional Anesthesia and Pain Management.
We searched MEDLINE, EMBASE, and the Cochrane Central Register of Controlled Trials for studies published prior to September 2019 on acetaminophen in primary TJA. All included studies underwent qualitative and quantitative homogeneity testing followed by a systematic review and direct comparison meta-analysis to assess the efficacy and safety of acetaminophen.
In total, 1287 publications were critically appraised yielding 17 publications representing the best available evidence for analysis. Oral and IV acetaminophen demonstrates the ability to safely reduce postoperative pain and opioid consumption during the inpatient hospital stay. No evidence was available to assess the efficacy and safety of oral acetaminophen after discharge.
Moderate evidence supports the use of oral and IV acetaminophen as a non-opioid adjunct for pain management during the inpatient hospitalization. Strong evidence supports the safety of oral and IV acetaminophen when appropriately administered to patients undergoing primary TJA. Although there is lack of robust evidence for use of acetaminophen following discharge, it remains a low-cost and low-risk option as part of a multimodal pain regimen.
在接受初次全膝关节置换术(TJA)的患者中,口服和静脉(IV)用对乙酰氨基酚已广泛用作多模式疼痛管理方案的一部分。我们研究的目的是评估对乙酰氨基酚的疗效和安全性,以支持美国髋关节和膝关节外科医师协会、美国矫形外科医师学会、髋关节协会、膝关节协会和美国区域麻醉和疼痛管理协会的联合临床实践指南。
我们在 MEDLINE、EMBASE 和 Cochrane 对照试验中心注册库中检索了截至 2019 年 9 月发表的关于初次 TJA 中使用对乙酰氨基酚的研究。所有纳入的研究均进行了定性和定量同质性测试,然后进行系统评价和直接比较荟萃分析,以评估对乙酰氨基酚的疗效和安全性。
总共批判性地评价了 1287 篇出版物,其中有 17 篇代表了最佳的现有证据进行分析。口服和 IV 用对乙酰氨基酚可安全地降低住院期间术后疼痛和阿片类药物的消耗。没有证据可评估出院后口服对乙酰氨基酚的疗效和安全性。
中度证据支持将口服和 IV 用对乙酰氨基酚作为住院期间非阿片类药物辅助治疗疼痛的方法。口服和 IV 用对乙酰氨基酚在适当给予接受初次 TJA 的患者时具有安全性。尽管缺乏出院后使用对乙酰氨基酚的有力证据,但它仍然是多模式疼痛治疗方案的一种低成本、低风险的选择。